Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 125 versus PHENYTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 125 versus PHENYTEX.
DILANTIN-125 vs PHENYTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Also enhances GABA-mediated inhibition.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
300-400 mg/day orally in divided doses, typically 100 mg three times daily or 200 mg twice daily; loading dose 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) at 2-hour intervals, or 10-15 mg/kg IV at a rate not exceeding 50 mg/min.
None Documented
None Documented
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
22 hours (range 7-42 hours; prolonged in hepatic impairment; clinical context: steady-state achieved in 5-7 days)
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Renal (hepatic metabolism to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal excretion minimal)
Category C
Category C
Anticonvulsant
Anticonvulsant